Elixir Drugs Private Limited
About Elixir Drugs Private Limited
Data last updated:
Elixir Drugs Private Limited is a private limited company based in Meerut, Uttar Pradesh, India. It operates in the ayurvedic products and services segment of the healthcare sector. It was incorporated on 08 April 2008 and has been in existence for over 18 years.
The company is registered with the Registrar of Companies (ROC), Uttar Pradesh, under CIN U24233UP2008PTC034961. Its GSTIN is 09AABCE9774B1ZI (Uttar Pradesh).
The company has an authorised share capital of ₹3 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Anupma Saxena and Sanjay Saxena.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 138 New Hanuman Puri Suraj Kund Road, Meerut, Uttar Pradesh, India – 250002.
As per the financials filed for FY 2024, the company reported a revenue of ₹8.91 Lakh, a decline of 71% compared to the previous year. For the same year it recorded a net loss of ₹2.16 Lakh (net margin -24.3%) and EBITDA of -₹2.16 Lakh (EBITDA margin -24.2%). Revenue has declined at a compounded annual rate (CAGR) of 31% over three years and 25% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address138 New Hanuman Puri Suraj Kund Road, Meerut, Uttar Pradesh, India – 250002
- IndustryHealthcare, Ayurvedic Products & Services
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Elixir Drugs Private Limited
The main business activity of Elixir Drugs is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Elixir Drugs Private Limited FY 2025 filings available
Elixir Drugs Private Limited reported revenue of ₹8.91 Lakh (down 71% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR) of Elixir Drugs Private Limited
Revenue has declined at a compounded annual rate (CAGR) of 25% over five years, including a 71% fall in the latest year. EBITDA fell 286% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Elixir Drugs Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | -₹2.16 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹2.16 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Elixir Drugs Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -24.2% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -24.3% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Elixir Drugs are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Elixir Drugs Private Limited
Elixir Drugs Private Limited is compared with the companies closest to it by revenue in the Healthcare industry (Ayurvedic Products and Services). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Ashvakarna Herbs Private Limited | ₹9.3 Lakh (FY 2020) | •••• | •••• | 41.0% | •••• | Delhi, India |
| Asthithwa Health and Wellbeing Private Limited | ₹9.05 Lakh (FY 2025) | •••• | •••• | -51.0% | •••• | Bangalore, Karnataka, India |
| Adya Herbal Private Limited | ₹9.02 Lakh (FY 2024) | •••• | •••• | -64.0% | •••• | Pune, Maharashtra, India |
| Apsada Enterprises Private Limited | ₹9 Lakh (FY 2025) | •••• | •••• | •••• | Dankuni, West Bengal, India | |
| Kimalaya Naturals Private Limited | ₹8.99 Lakh (FY 2025) | •••• | •••• | -45.0% | •••• | Almora, Uttarakhand, India |
| Elixir Drugs Private Limited this company | ₹8.91 Lakh (FY 2024) | •••• | •••• | -71.0% | •••• | Meerut, Uttar Pradesh, India |
| Sandipani Ayurveda Private Limited | ₹8.89 Lakh (FY 2024) | •••• | •••• | -49.0% | •••• | Haridwar, Uttarakhand, India |
| Phytomics Private Limited | ₹8.79 Lakh (FY 2025) | •••• | •••• | -91.0% | •••• | Coimbatore, Tamil Nadu, India |
| Vedamruth Health Sciences Private Limited | ₹8.62 Lakh (FY 2025) | •••• | •••• | -6.0% | •••• | Aluva, Kerala, India |
| Vedic Biotechnologies Private Limited | ₹8.6 Lakh (FY 2025) | •••• | •••• | 21.0% | •••• | New Delhi, Delhi, India |
| Kairali Ayurvedic Products Private Limited | ₹8.51 Lakh (FY 2022) | •••• | •••• | 229.0% | •••• | New Delhi, Delhi, India |
Peers are the five companies nearest above and the five nearest below Elixir Drugs by revenue in the Healthcare industry (Ayurvedic Products and Services), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Elixir Drugs Private Limited
Elixir Drugs Private Limited is audited by VIKAS & CO. for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| VIKAS & CO. | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Elixir Drugs Private Limited
Elixir Drugs has 2 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anupma Saxena | Director | 01 Nov 2011 | 14 Years 11 Months | Current |
| Sanjay Saxena | Director | 08 Apr 2008 | 18 Years 6 Months | Current |
Ownership and Shareholding of Elixir Drugs Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Elixir Drugs Private Limited
Elixir Drugs Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Elixir Drugs Private Limited
Employment history and EPFO contributions of people linked to Elixir Drugs.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Elixir Drugs Private Limited
Elixir Drugs Private Limited has 5 board changes on record since 2008: 2 appointments and 3 cessations. The latest: Savita Tyagi ceased to be Director on 23 Sep 2013.
Credit Ratings, Litigation & Regulatory Alerts for Elixir Drugs Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Elixir Drugs Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Elixir Drugs Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Elixir Drugs Private Limited
Elixir Drugs has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AABCE9774B1ZI | Uttar Pradesh | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Elixir Drugs Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Elixir Drugs Private Limited
Elixir Drugs is an active private limited company based in Meerut, Uttar Pradesh, India. The company works in ayurvedic products and services, within the healthcare industry. It was incorporated on 08 April 2008 (18+ years old) and is registered under CIN U24233UP2008PTC034961.
Elixir Drugs reported revenue of ₹8.91 Lakh for FY 2024 (down 71% YoY).
Elixir Drugs has 2 current directors:
- Anupma Saxena - Director
- Sanjay Saxena - Director
Elixir Drugs reported a net loss of ₹2.16 Lakh (net margin -24.3%) and EBITDA of -₹2.16 Lakh (EBITDA margin -24.2%) for FY 2024, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Elixir Drugs is -31% over three years and -25% over five years. In the latest year (FY 2024) revenue fell 71%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Elixir Drugs is 09AABCE9774B1ZI, registered in Uttar Pradesh.
The CIN (Corporate Identification Number) of Elixir Drugs is U24233UP2008PTC034961. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Elixir Drugs was incorporated on 08 April 2008, making it 18+ years old. It is registered with the Registrar of Companies, Uttar Pradesh.
The peers of Elixir Drugs by revenue are Ashvakarna Herbs Private Limited, Asthithwa Health and Wellbeing Private Limited, Adya Herbal Private Limited, Apsada Enterprises Private Limited, Kimalaya Naturals Private Limited and 5 more, all in the Healthcare industry (Ayurvedic Products and Services).
Savita Tyagi ceased to be Director on 23 Sep 2013. Anupma Saxena was appointed as Director on 01 Nov 2011. Girish Tyagi ceased to be Director on 13 Mar 2010. Elixir Drugs has 5 board changes on record in total.
The registered office of Elixir Drugs is at 138 New Hanuman Puri Suraj Kund Road, Meerut, Uttar Pradesh, India – 250002.